Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 31, 2014. The report primarily disseminates an LSE Announcement issued on March 30, 2014, regarding the results of the Phase III STABILITY clinical trial for the investigational drug darapladib.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory report of a specific clinical trial outcome and does not contain financial statements or quarterly financial results.
Material Changes and Clinical Trial Results
The filing details the results of the STABILITY study, a global, double-blind, event-driven trial involving 15,828 patients with chronic coronary heart disease (CHD). Key findings include:
- Primary Endpoint: The study did not meet its primary endpoint. There was no statistically significant difference in the time to first occurrence of Major Adverse Cardiovascular Events (MACE) between the darapladib group (9.7%) and the placebo group (10.4%). The hazard ratio (HR) was 0.94 (95% CI 0.85 - 1.03, p=0.199).
- Secondary Endpoints: Nominal statistical significance was observed for major coronary events (HR 0.90, p=0.045) and total coronary events (HR 0.91, p=0.019).
- Mortality and Stroke: No difference was observed in all-cause mortality (7.3% in both groups) or stroke (HR 1.01).
- Safety: Serious adverse events occurred in 43% of the darapladib group versus 44% in the placebo group. Discontinuation due to adverse events was higher in the darapladib group (20%) compared to placebo (14%).
Guidance, Outlook, and Management Commentary
Management commentary indicates that while the lack of effect on stroke was disappointing, the potential reduction in coronary events warrants further investigation. GSK is awaiting results from the second Phase III study, SOLID-TIMI 52, which evaluates darapladib in patients with acute coronary syndrome. Results for SOLID-TIMI 52 are expected in the second quarter of 2014. The filing includes a standard cautionary statement that forward-looking statements are subject to risks and uncertainties.
Key Facts for Investor Verification
- Darapladib is not currently approved for use anywhere in the world.
- The STABILITY study failed to meet its primary endpoint for MACE reduction.
- Results from the ongoing SOLID-TIMI 52 trial are critical for determining the future development of darapladib.
- Discontinuation rates due to adverse events were higher in the treatment group than the placebo group.
- This filing contains no financial performance data; investors should refer to GSK's Annual Report on Form 20-F for financial metrics.